All treatments
InjectionWeight LossIn stock

Ozempic® injection

Branded once-weekly semaglutide, one of the most-recognized GLP-1 pens in the weight-loss conversation. Run an Ozempic®-aware weight-loss program with intake, billing, refill, and pharmacy workflows wired into one backend.

Launch this programSee the stack
Ozempic semaglutide pen
Dose
Once weekly
Typical loss · 68 wks
−6% to −10%
Format
Weekly subcutaneous pen injection
Dose range
0.25 mg to 2.0 mg once weekly
Rx required
Yes, licensed provider review
Use case
Weight management at low to mid GLP-1 doses
About the medication

The semaglutide brand patients ask for by name

Ozempic® is Novo Nordisk's branded once-weekly semaglutide. While it is FDA-labeled for type 2 diabetes, it is one of the most-recognized GLP-1 pens in the weight-management conversation. Real-world weight loss at the 1.0 mg to 2.0 mg dose levels typically runs between 6% and 10% over 6 to 12 months, making it a common starting point for patients new to GLP-1s for weight loss.

  • Same molecule as Wegovy® but capped at a 2.0 mg weekly maintenance dose
  • Useful entry point for weight-loss patients who recognize Ozempic® specifically
  • Slower weight curve than Wegovy® due to the lower maintenance ceiling
  • Helps programs serve patients who arrive asking for the brand by name
Mechanism
GLP-1 receptor agonist, appetite and satiety pathway
Delivery
Pre-filled multi-dose pen, once weekly subcutaneous
Onset
Appetite changes in days, weight loss builds over months
Oversight
Provider review for indication, history, and dose escalation
Expected results

Meaningful, dose-dependent weight loss for a brand-name semaglutide

Ozempic® weight outcomes vary by maintenance dose. Real-world data show roughly 6% body weight loss at 1.0 mg and 9% to 10% at 2.0 mg over 40 to 68 weeks. Higher weight-loss outcomes generally require the higher Wegovy® dosing.

~7–10%
Avg. weight loss at 2.0 mg
in real-world weight-management use over ~12 months
majority
Patients losing ≥5%
of adherent patients on the higher 2.0 mg dose
subset
Patients losing ≥10%
typically requires the full 2.0 mg maintenance dose
Mean change in body weight
% change from baseline · weeks 0–68
Ozempic® 2.0 mgPlacebo
At week 68
−9.9%
Ozempic® 2.0 mg
At week 68
−2.1%
Placebo
Net difference
−7.8 pts
vs. placebo

Illustrative, based on real-world Ozempic® 2.0 mg observations and published semaglutide trial outcomes. Ozempic® is FDA-labeled for type 2 diabetes; use for chronic weight management is off-label and at provider discretion.

Dosing protocol

Standard titration schedule

Ozempic® labeling escalates from 0.25 mg weekly to 2.0 mg with at least 4 weeks between increases. In weight-management programs, providers commonly hold patients at 1.0 mg or 2.0 mg depending on response and tolerability.

  1. 1
    Weeks 1–4
    0.25 mg
    Initiation only, GI tolerance
  2. 2
    Weeks 5–8
    0.5 mg
    First up-titration
  3. 3
    Weeks 9–12
    1.0 mg
    Common weight-management dose
  4. 4
    Week 13+
    2.0 mg
    Higher maintenance for added weight effect
The Turbopills stack for this program

Everything you need to run an Ozempic®-aware weight-loss program

Pick the pieces you want. Use your own brand, your own providers, your own price, powered by a single, compliant backend.

Product website & ad landing pages
Turbopills AI Studio — ad images & videos
Beta
Dynamic intake forms
Billing & subscriptions
Provider review & e-Rx
Pharmacy order routing
Refills & auto-ship
Patient communications
Experiments & A/B tests
Beta
Ready to launch

Launch an Ozempic®-aware weight-loss program in weeks, not quarters.

The platform ships the intake flow, billing, subscriptions, refill workflows, and the operator console your team works in. Bring your licensed providers and pharmacy partners; we wire everything into one backend so you launch in weeks, not quarters.

Talk to our teamBrowse treatments

Marketing and educational content only. Clinical details on this page are summarized from publicly available sources to help operators scope a program — they are not medical advice, dosing instructions, or a recommendation for any individual patient. Real patient care requires a licensed provider and a compliant pharmacy partner; Turbopills provides the software that helps brands run the program around them.

Trademark notice. Ozempic® is a registered trademark of Novo Nordisk A/S. Turbopills is not affiliated with, endorsed by, or sponsored by Novo Nordisk. References to the brand are for educational and operator-scoping purposes only.

Related

Other weight-loss treatments